Clinical trials: Verruca Vulgaris
Verruca Vulgaris, Molluscum Contagiosum
Cold Atmospheric Plasma Device Extension Study
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one…
- Trial name
- NCT05937672
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Warts
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN…
- Trial name
- NCT02393417
- Testing
- CANDIN
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nielsen BioSciences, Inc.
Common Warts, HPV (Human Papillomavirus)
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata…
- Conditions
- Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
- Trial name
- NCT02640820
- Testing
- Sensitizing DPCP Ointment, Treatment DPCP Ointment
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Verruca Plantaris
A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts.
To evaluate the efficacy of bleomycin and cryopreservation in the treatment of plantar verruca by dermoscopy and explore the influencing factors.
- Trial name
- NCT06718192
- Testing
- Bleomycin injection, Cryotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Warts
Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris
Photodynamic therapy (PDT) has been developed as a promising new cancer treatment modality, which involves the uptakes of a photosensitizer by tumor cells, followed by the activation of photosensitizer with approximate wavelength…
- Trial name
- NCT00155584
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-3 (NCT07637734)
- Testing
- VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
- Where
- 20 sites in United States, Japan
- Volunteers
- 300 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Verruca Viral
Gardasil Versus Cervarix in the Treatment of Warts
Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or…
- Trial name
- NCT05383625
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Bivalent Human Papilloma Virus Vaccine, Saline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Zagazig University
Verruca (Warts)
A Comparative Study of Occlusive Heat Patch in the Treatment of Warts
The goal of this study is to determine the safety and efficacy of the occlusive heat patch for the treatment of verrucae (warts).
- Trial name
- NCT01746056
- Testing
- Occlusive Heat Patch
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Yale University
Verruca Vulgaris, Warts
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
- Conditions
- Verruca Vulgaris, Warts, Common Wart
- Trial name
- NCT05799157
- Testing
- VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
- Where
- 16 sites in United States
- Volunteers
- 153 people
- Sponsor
- Veradermics, Inc.
Warts, Human Papilloma Virus
Candin Safety & Efficacy Study for the Treatment of Warts
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
- Trial name
- NCT01757392
- Testing
- Candida albicans Skin Test Antigen
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Nielsen BioSciences, Inc.
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Verruca Vulgaris, Healthy
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.
- Trial name
- NCT05409365
- Testing
- Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Warts
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact).
- Trial name
- NCT00546611
- Testing
- PEP005
- Where
- Australia
- Sponsor
- Peplin
Common Wart
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
- Trial name
- NCT01796795
- Testing
- Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM
- Volunteers
- 102 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-2 (NCT07246590)
- Testing
- VP-102, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 302 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Warts, Warts Hand
CellFX System for the Treatment of Cutaneous Non-Genital Warts
This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.
- Conditions
- Warts, Warts Hand, Verruca
- Trial name
- NCT04554394
- Testing
- CellFX Device
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pulse Biosciences, Inc.
Common Warts (Verruca Vulgaris), Common Warts
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4.
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-4 (NCT07457918)
- Testing
- Cantharidin
- Where
- 12 sites in United States, Japan
- Volunteers
- 250 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Plantar Wart
Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts
Plantar warts can be bothersome and painful requiring treatment. The investigators will compare the efficacy of pyruvic acid and salicylic acid in treating multiple plantar warts.
- Trial name
- NCT02151630
- Testing
- Pyruvic acid, Salicylic Acid
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Isfahan University of Medical Sciences
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Actinic Keratosis, Acne/Rosacea
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
- Conditions
- Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea
- Trial name
- NCT02759900
- Testing
- Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Skin Center Dermatology Group